New Topical Cream Significantly Reduces Severe Radiation Skin Damage in Breast Cancer Patients

Radiotherapy is a cornerstone treatment for breast cancer, but it frequently causes radiation dermatitis, a painful inflammatory skin reaction. These reactions can range from redness to severe blistering, often leading to significant discomfort, dose interruptions, and reduced quality of life for patients. While various lotions are used prophylactically, there remains a critical need for more effective topical agents to prevent and mitigate severe radiation-induced skin damage.

The study revealed a statistically significant difference in the incidence of severe skin reactions between the two groups. Patients treated with Thêta-Cream experienced substantially fewer grade 2 radiation dermatitis reactions, with only 28% of this group affected, compared to 48% in the Bepanthol lotion group (p=0.04). Crucially, grade 3 radiation dermatitis, which involves moist desquamation and significant discomfort, was completely absent (0%) in the Thêta-Cream cohort, whereas 6% of patients using Bepanthol lotion developed these severe reactions (p=0.03). This indicates that Thêta-Cream led to a 41.7% relative reduction in grade 2 reactions and a 100% relative reduction in grade 3 reactions compared to the control lotion, demonstrating superior prophylactic efficacy against severe radiation-induced skin damage.